Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines

Abstract

Cytokines dimerize their receptors, with binding of the “second chain” triggering signaling. In the interleukin (IL)-4/13 system, different cell types express varying levels of alternative second receptor chains (γc or IL-13Rα1), forming functionally distinct Type-I or Type-II complexes. We manipulated the affinity and specificity of second chain recruitment by human IL-4. A Type-I receptor-selective IL-4 ‘superkine’ with 3700-fold higher affinity for γc was 3-10 fold more potent than wild-type IL-4. Conversely, a variant with high affinity for IL-13Rα1 more potently activated cells expressing the Type-II receptor, and induced differentiation of dendritic cells from monocytes, implicating the Type-II receptor in this process. Superkines exhibited signaling advantages on cells with lower second chain levels. Comparative transcriptional analysis reveals that the superkines induce largely redundant gene expression profiles. Variable second chain levels can be exploited to redirect cytokines towards distinct cell subsets and elicit novel actions, potentially improving the selectivity of cytokine therapy.

“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis

“…Random mutagenesis and site-directed mutagenesis of interface contact residues and/or residues that do not directly contact but contribute to the structural integrity of a protein-protein interface account for the success of a vast majority of protein engineering approaches to increase binding affinity for ligand-receptor interactions (22,(55)(56)(57)(58). However, this was not the case with CD47 (Fig.…”

Commentary: IL-4 and IL-13 receptors and signaling

“…The γC and IL-13Rα1 subunits have lower, approximately equal affinity for the IL-4:IL-4Rα complex (K D = 500 nM). Therefore, the availability of each chain on the cell surface determines the signaling pathway activated within the responding cell (4, 5). While the IL-4Rα and IL-13Rα1 chains are widely expressed at low levels on most cell types, the γC chain is primarily expressed on hematopoietic immune cells.…”

Lessons from immunology: IL4R directly promotes mammary tumor metastasis

“…Fortunately, modified IL4 ligands termed "superkines" that selectively target and inhibit the type II IL4R are in development. 10 Further experimentation is needed to determine if IL4 superkines can thwart metastatic tumor growth.…”